Novo Nordisk\u2019s stock has clawed back more than 40% from its March nadir, yet the Danish drugmaker\u2019s latest week was a study in contrasts. A promising readout for its experimental hemophilia A candidate Denecimig and the commercial rollout of a once-weekly insulin in India were balanced by the quiet withdrawal of a Phase 2 obesity device study, all while a massive buyback programme continues to steady the ship. The B-share closed Friday at \u20ac43.32, up 1.29% on the day, though the seven-day performance eked out only a 0.41% decline as the equity consolidates after a sharp rebound.<\/p>\n
Positive data from the FRONTIER4 Phase 3 extension trial landed on July 11 at the International Society on Thrombosis and Haemostasis congress in Paris. The interim analysis covered 426 patients aged one year and older \u2014 365 adolescents and adults with a median observation of six months, and 61 children tracked for a median of four months. Denecimig (Mim8), administered subcutaneously once monthly, every two weeks, or weekly, showed a safety profile consistent with earlier studies. Injection-site reactions were rare: 2.0% of injections in children and 1.8% in adolescents and adults, all mild and transient. Martin Holst Lange, head of R&D, said the data confirm Denecimig\u2019s potential as a prophylactic treatment regardless of inhibitor status or dosing frequency. The drug is already under review by the U.S. Food and Drug Administration following a submission earlier this year. While Denecimig remains a small piece of Novo Nordisk\u2019s diversification beyond its GLP-1 core, the FRONTIER4 results strengthen the hemophilia franchise alongside the established Alhemo.<\/p>\n
Less visible but noteworthy was the withdrawal of a Phase 2 study for CagriSema, a candidate targeting type-2 diabetes and obesity. The trial, officially pulled on July 7, was designed to compare two different injection systems for the combination therapy. Analysts view the move as a manageable risk \u2014 it does not directly threaten near-term revenue from the current GLP-1 portfolio \u2014 but it casts a shadow over the company\u2019s device strategy for the next generation of obesity treatments. The focus may now shift to other Phase 3 programmes, leaving competitors more breathing room in the obesity space.<\/p>\n